Cryo-Cell International, Inc. (CCEL) Fair Value 2026

CCEL · Medical Care Facilities ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.7 /10

32 fundamental signals · 8 models active

Value Trap Risk

SAFE (19/100)

Quick Summary — As of 2026-08-28, Cryo-Cell International, Inc. (CCEL) trades at $4.00, versus a $5.60 median fair value across its 8 active models — 40.1% above the current price. QOC: 6.7/10. Value Trap Risk: 19/100 (SAFE). 8/13 models active. Within that set, the Bayesian DCF component alone returns $6.68.

Key Facts

Ticker
CCEL
Price
$4.00
Quality Score
6.7/10
Value Trap Risk
19/100
Models Active
8/13
Last Updated
Strength: RCMH-DCF suggests +68.6% upside with 61% confidence
Risk: Limited model coverage (8/13) may reduce confidence

Is Cryo-Cell International, Inc. (CCEL) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Cryo-Cell International, Inc. (CCEL) appears undervalued as of : the median of 8 independent fair value estimates is $5.60, 40.1% above the current price of $4.00. Estimates range from $0.19 to $6.74. CCEL scores 6.7/10 on fundamental quality and 19/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. CCEL’s +40.1% gap is wider than that market norm, and the Medical Care Facilities sector median is -28.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Cryo-Cell International, Inc. Stock in 2026? →

What Fair Value Does Each Model Give CCEL?

8 Intrinsic Value Models vs. Current Price ($4.00)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $6.68 +67.0%
Intrinsic · High Conviction
 $0.63 -84.2%
Ensemble · Low Conviction
 $5.01 +25.2%
Intrinsic · High Conviction
 $6.74 +68.6%
Unlock the Full Matrix

Access 4 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is CCEL's Fair Value Range?

Spread across 8 independent models · $0.19 to $6.74

CirclFi's 8 active models place Cryo-Cell International, Inc. (CCEL) between $0.19 and $6.74 per share, a spread of 117% of the median. The median of that range — $5.60 — is the fair value CirclFi publishes for CCEL, against a current price of $4.00.

Low · Regime CrossHigh · RCMH-DCF
$0.19median $5.60$6.74
Where the range comes from
Most bearish modelRegime Cross-Sectional$0.19
Most bullish modelRCMH-DCF$6.74
Model agreement5 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CCEL. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CCEL, not a CirclFi price target. How each model works →

What Is Cryo-Cell International, Inc. (CCEL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Cryo-Cell International, Inc. at $4.00. With an estimated intrinsic value of $5.60 and 5 of 8 models pointing higher, the median implied return is +40.1%. The most optimistic model, RCMH-DCF, places fair value at $6.74 (+68.6%), while Regime Cross — the most conservative — estimates $0.19 (-95.2%). This +163.8% gap reflects genuine analytical uncertainty about Cryo-Cell International, Inc.'s intrinsic worth. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About CCEL?

8 of 13 models are currently active for CCEL. Of these, 5 models suggest upside while 3 models suggest overvaluation. Taken together, their median fair value for CCEL is $5.60 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $6.68 on its own, implying +67.0% upside from the current price. See which stocks rank higher →

How Does CCEL Rank in Medical Care Facilities?

Among 60 Medical Care Facilities stocks, CCEL ranks #31 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.

See all Most Undervalued Medical Care Facilities Stocks →

Cryo-Cell International, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is CCEL a Value Trap?

CirclFi's Value Trap algorithm assigns CCEL a score of 19/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Cryo-Cell International, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Cryo-Cell International, Inc.'s fundamental quality profile registers 6.7/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +163.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CCEL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CCEL's 8 active models, average confidence is 50%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cryo-Cell International, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Care Facilities Stocks Should You Also Analyze?

10 related Medical Care Facilities stocks with 13-model coverage

AVAHAveanna Healthcare Holdings Inc.QOC 6.7SRTAStrata Critical Medical, Inc.QOC 6.5INNVInnovAge Holding Corp.QOC 6.7SGRYSurgery Partners, Inc.QOC 6.4AMNAMN Healthcare Services, Inc.QOC 6.7RHEPRegional Health Properties, Inc.QOC 6.2ACHCAcadia Healthcare Company, Inc.QOC 5.6ADUSAddus HomeCare CorporationQOC 8.9HCSGHealthcare Services Group, Inc.QOC 7.7NHCNational HealthCare CorporationQOC 8.7

Read investment analysis: AVAH · SRTA · INNV · SGRY · AMN · RHEP · ACHC · ADUS · HCSG · NHC

Which Other Stocks Have a Similar Quality Score to CCEL?

6 companies across all industries closest to CCEL’s Quality of Company score of 6.7/10.

LASRnLIGHT, Inc.QOC 6.7NAMMNamib MineralsQOC 6.7LAWCS Disco, Inc.QOC 6.7TBITrueBlue, Inc.QOC 6.7AXTIAXT, Inc.QOC 6.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LASR · NAMM · LAW · TBI · AXTI · NVDA

Where Does CCEL Sit in CirclFi's Medical Care Facilities Rankings?

CCEL is ranked against every other Medical Care Facilities stock CirclFi covers in each of these screens.

See all Medical Care Facilities stocks ranked →

What Else Do Investors Ask About Cryo-Cell International, Inc.’s Valuation?

What is Cryo-Cell International, Inc.'s intrinsic value in 2026?

CirclFi puts Cryo-Cell International, Inc. (CCEL)'s intrinsic value at $5.60 — the median of 8 independent model estimates as of 2026-08-28, ranging from $0.19 to $6.74. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $6.68 on its own. The Quality of Company score is 6.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CCEL overvalued or undervalued right now?

At $4.00, 5 of 8 active models suggest CCEL may be undervalued, while 3 indicate potential overvaluation. The median of all 8 fair value estimates is $5.60, 40.1% above the current price of $4.00 — a consensus view that CCEL is undervalued. The assessment depends on which methodology best fits Cryo-Cell International, Inc.'s business model in Medical Care Facilities.

What does a Quality of Company score of 6.7 mean for CCEL?

Cryo-Cell International, Inc.'s QOC of 6.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CCEL?

CirclFi analyzes CCEL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CCEL?

Of the 8 models currently active on CCEL, RCMH-DCF is the most bullish at $6.74 per share, and Regime Cross-Sectional is the most bearish at $0.19. CirclFi's published fair value for CCEL is the median of that range, $5.60, not either extreme. The gap between the two ends equals 117% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CCEL a value trap in 2026?

Cryo-Cell International, Inc.'s Value Trap score is 19/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Cryo-Cell International, Inc. (CCEL) has a median fair value of $5.60 — 40.1% above the current price of $4.00 — as of 2026-08-28.” Source: circlfi.com/stock/CCEL/ · Methodology
Primary sources for this CCEL valuation
  • Financial statements: Cryo-Cell International, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000862692) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CCEL as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on CCEL.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for CCEL Unlock All 8 — $39/mo